Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says

Kymera Therapeutics (NASDAQ:KYMR) had its target price lifted by equities research analysts at Guggenheim from $45.00 to $52.00 in a report released on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential upside of 11.90% from the stock’s previous close.

KYMR has been the subject of several other research reports. Oppenheimer increased their price target on Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, September 27th. B. Riley lifted their target price on shares of Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 9th. Leerink Partnrs upgraded shares of Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Morgan Stanley lifted their price objective on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 14th. Finally, Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Monday, September 9th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $49.15.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $46.47 on Friday. Kymera Therapeutics has a 52-week low of $9.60 and a 52-week high of $53.27. The company has a 50-day simple moving average of $47.04 and a 200 day simple moving average of $40.70.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 28.05%. The company had revenue of $3.74 million during the quarter, compared to analyst estimates of $10.34 million. During the same quarter last year, the business posted ($0.90) EPS. Kymera Therapeutics’s quarterly revenue was down 20.9% compared to the same quarter last year. As a group, analysts anticipate that Kymera Therapeutics will post -2.85 earnings per share for the current year.

Insider Activity

In related news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Kymera Therapeutics news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company’s stock.

Institutional Trading of Kymera Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Values First Advisors Inc. purchased a new position in Kymera Therapeutics in the 3rd quarter worth $61,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Kymera Therapeutics by 27.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after acquiring an additional 504 shares during the period. Comerica Bank grew its position in Kymera Therapeutics by 13.7% during the 1st quarter. Comerica Bank now owns 3,324 shares of the company’s stock worth $134,000 after acquiring an additional 400 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Kymera Therapeutics by 7.8% in the first quarter. Ameritas Investment Partners Inc. now owns 4,070 shares of the company’s stock valued at $164,000 after purchasing an additional 295 shares during the last quarter. Finally, Public Employees Retirement Association of Colorado bought a new stake in Kymera Therapeutics in the second quarter valued at approximately $139,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.